Louis Lehot on Biotech IPOs – 'Biotech could have a great fourth quarter'
September 4, 2024
Bloomberg Law
Foley & Lardner LLP partner Louis Lehot offered insight on the biotech industry’s upcoming initial public offerings in the Bloomberg Law article, “Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch.”
“Biotech could have a great fourth quarter, we have a great pipeline,” Lehot commented, as several biotech companies look to reignite the sector with upcoming IPOs. “Biotech IPOs are here and ready to put money to work.”
(Subscription required)
People
Related News
October 9, 2026
In the News
Jonathan Lasken Highlighted Across the Media for Arrival to Foley
Foley & Lardner LLP partner Jonathan Lasken is highlighted across the media for his recent arrival to the firm’s Washington D.C. office.
October 7, 2026
In the News
William Holtz Examines New FDA Approach to Clinical Trial Development
Foley & Lardner LLP of counsel William Holtz is quoted in the PharmaVoice article, “5 Key Facts About the FDA Expedited IND Pilot Program,” examining the FDA's new pilot program and its potential to accelerate clinical research.
October 5, 2026
In the News
Louis Lehot Analyzes U.S. IPO Market Trends and Outlook
Foley & Lardner LLP partner Louis Lehot is featured in the Daily Journal‘s Capital & Counsel newsletter offering insights on the current state of the U.S. IPO market and the factors influencing companies' routes to going public.